June has been a very exciting month for Biobide, as we have had the opportunity to attend three major events in USA.
As every year, we started the month attending the largest global event for biotechnology industry, the 2019 BIO International Convention, this year in Philadelphia and represented by ADL Bionatur Solutions the European biotech leader group which Biobide belongs to. Moreover, during the 17-20th we could participate in the Boston 18th Annual World Preclinical Congress (World Pharma Week). This event delivered a cutting-edge agenda, where more than 1500 assitants came together and exchange expertise and opinions in preclinical research and translation across all therapeutic areas. Moreover, Biobide USA’s CEO, Arantza Muriana had the opportunity to deliver our latest presentation, named as ‘Zebrafish Models for Early Research and Development in Neurodegenerative and Neuromuscular Diseases, where modes such as ALS, Duchenne, Dravet Syndrome their application in CNS drug screening and target validation were reviewed.
Last but not least, during the 23-26th, Biobide took part in the 59th Teratology Society Meeting (TSM) in San Diego. The TSM is the premier source for leading research related to birth defects and other disorders of developmental origin. Attendees could gain insight into the causes and prevention of birth defects and disorders of developmental origin. This time, Ms. Muriana, presented Biobide’s latest poster, in collaboration with L’Oreal: ‘Zebrafish and Medaka as Alternative Models for Developmental Toxicity Assessment of Chemicals (Including Behavior as An End Point)’, which is an study focused on the comparison of the potential of both zebrafish and medaka, for the teratogenicity assessment of chemicals.
If you want to obtain more information or schedule a meeting, please contact us via email email@example.com